KYMERA THERAPEUTICS TO ANNOUNCE KT-621 BROADEN2 PHASE 2B ATOPIC DERMATITIS TRIAL RESULTS ON NOVEMBER 23, 2026

Reuters · 12h ago

Please log in to view news